What pharmaceutical form is DEPO-PROGEVERA 150 mg/ml SUSPENSION INYECTABLE available in?

DEPO-PROGEVERA 150 mg/ml SUSPENSION INYECTABLE: SUSPENSIÓN INYECTABLE 150 mg (VÍA INTRAMUSCULAR)

What are the side effects of DEPO-PROGEVERA 150 mg/ml SUSPENSION INYECTABLE?

You can help ensure medicines are safe by reporting the side effects you experience. You can report side effects to your doctor, or directly at www.tga.gov.au/reporting-problems

Does DEPO-PROGEVERA 150 mg/ml SUSPENSION INYECTABLE interact with other medications?

MPA increases the risk ofbreast cancer,dementia, andthrombuswhen used in combination with CEEs to treatmenopausal symptoms.When used as a contraceptive, MPA does not generallyinteractwith other medications. The combination of MPA withaminoglutethimideto treatmetastasesfrom breast cancer has been associated with an increase indepression.St John's wortmay decrease the effectiveness of MPA as a contraceptive due to acceleration of itsmetabolism.

Can DEPO-PROGEVERA 150 mg/ml SUSPENSION INYECTABLE be used during pregnancy?

( AHT ) For the active ingredient methylprednisolone acetate You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

What ATC class does DEPO-PROGEVERA 150 mg/ml SUSPENSION INYECTABLE belong to?

DEPO-PROGEVERA 150 mg/ml SUSPENSION INYECTABLE: ATC G03D. ATC is the WHO Anatomical Therapeutic Chemical classification — it groups drugs by organ system and pharmacological mechanism.

DEPO-PROGEVERA 150 mg/ml SUSPENSION INYECTABLE

This information is for educational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional.

AU:D G03AC06(WHO)G03DA02(WHO),L02AB02(WHO) AU:S4(Prescription only)CA:℞-onlyUS:℞-onlyIn general: ℞ (Prescription only) [(6S,8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate 71-58-9 6279 2879 DB00603 6043 C2QI4IOI2G C08150Y CHEBI:6716 ChEMBL717Y DTXSID0025527 Interactive image C[C@H]1C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)OC(=O)C)C)[C@@]4(C1=CC(=O)CC4)C InChI=1S/C24H34O4/c1-14-12-18-19(22(4)9-6-17(27)13-21(14)22)7-10-23(5)20(18)8-11-24(23,15(2)25)28-16(3)26/h13-14,18-20H,6-12H2,1-5H3/t14-,18+,19-,20-,22+,23-,24-/m0/s1Key:PSGAAPLEWMOORI-PEINSRQWSA-N Medroxyprogesterone acetate(MPA), also known asdepot medroxyprogesterone acetate(DMPA) ininjectableform and sold under the brand nameDepo-Proveraamong others, is ahormonal medicationof theprogestintype.It is used as a method ofbirth controland as a part ofmenopausal hormone therapy.It is also used to treatendometriosis,abnormal uterine bleeding,paraphilia, and certain types ofcancer.The medication is available both alone and in combination with anestrogen.It is takenby mouth, usedunder the tongue, or byinjection into a muscleorfat. Commonside effectsincludemenstrual disturbancessuch asabsence of periods,abdominal pain, andheadaches.More serious side effects includebone loss,blood clots,allergic reactions, andliver problems.Use is not recommended duringpregnancyas it mayharm the baby.MPA is anartificialprogestogen, and as suchactivatestheprogesterone receptor, thebiological targetofprogesterone.It also hasandrogenicactivity and weakglucocorticoidactivity. Due to its progestogenic activity, MPA decreases the body's release ofgonadotropinsand can suppresssex hormonelevels.It works as a form of birth control by preventingovulation. MPA was discovered in 1956 and was introduced for medical use in the United States in 1959.It is on theWorld Health Organization's List of Essential Medicines.MPA is the most widely used progestin in menopausal hormone therapy and inprogestogen-only birth control.DMPA is approved for use as a form of long-acting birth control in more than 100 countries.In 2023, it was the 257th most commonly prescribed medication in the United States, with more than 1million prescriptions.

DEPO-PROGEVERA 150 mg/ml SUSPENSION INYECTABLE

User Reviews